This project will develop and implement a training program in neurotherapeutics discovery and development for faculty members and advanced postdoctoral fellows, centered around a 3-day short course that will provide the trainees with the various knowledge elements required to discover and advance a neurotherapeutic agent to IND. Following the short course, the training program will continue for a two-year period in which students will have individualized mentoring and assessment. The training, which is designed to be applicable to diverse diseases of the nervous system, will equip students with a broad understanding of the various component steps in the neurotherapeutics drug discovery and development process. Students will learn how to identify a good drug discovery target;how to construct an assay;the elements of medicinal chemistry;how to conduct animal efficacy testing;the principles of ADME studies, safety testing, and formulation;the principles of experimental medicine and biomarkers;the steps required to prepare an IND document and the principles for interacting with the FDA;the principles of intellectual property as they relate to neurotherapeutics discovery and development;and how to seek funding for academic drug discovery research. They will also receive training in responsible conduct of research. Students will be equipped with the skills to develop and coordinate an entire drug discovery and development effort, and to work collaboratively with experts in each of the component areas. The training will combine didactic lectures with active engagement activities in which the students will be challenged to utilize the lecture material to work through their own drug discovery project plan with the guidance of the area experts. The 3-day short course (followed by two-years of mentorship and assessment) will be offered annually, a total of five times.
This project will train researchers to discover and develop new treatments for disorders of the brain and nervous system so as to reduce disability and lead to improved quality of life.
|Gamo, Nao J; Birknow, Michelle R; Sullivan, Danielle et al. (2017) Valley of death: A proposal to build a ""translational bridge"" for the next generation. Neurosci Res 115:1-4|
|Devinsky, Orrin; Vezzani, Annamaria; Najjar, Souhel et al. (2013) Glia and epilepsy: excitability and inflammation. Trends Neurosci 36:174-84|
|Rogawski, M A; Hanada, T (2013) Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl :19-24|
|Galanopoulou, Aristea S; Kokaia, Merab; Loeb, Jeffrey A et al. (2013) Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia 54 Suppl 4:13-23|
|Rogawski, M A (2013) AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl :9-18|